Cargando…

CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome

BACKGROUND: To investigate the contributions of CYP2C19 polymorphisms to the various clopidogrel responses tested by thrombelastography (TEG) in Chinese patients with the acute coronary syndrome (ACS). METHODS: Patients were screened prospectively with ACS diagnose and were treated with clopidogrel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jian, Nie, Xiao-Yan, Zhang, Yong, Lu, Yun, Shi, Lu-Wen, Wang, Wei-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717987/ https://www.ncbi.nlm.nih.gov/pubmed/26265611 http://dx.doi.org/10.4103/0366-6999.162515

Ejemplares similares

Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome
por: Peng, Wenxing, et al.
Publicado: (2019)

Is it possible? Predicting complications and morbidity in surgical patients on clopidogrel therapy with Thrombelastography Platelet Mapping
por: Callender, Rashida, et al.
Publicado: (2013)

Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA
por: Yang, Yingying, et al.
Publicado: (2020)

Thrombelastography Compared with Multiple Impedance Aggregometry to Assess High On-Clopidogrel Reactivity in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
por: Gjermeni, Diona, et al.
Publicado: (2022)

Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients
por: Olie, Renske H., et al.
Publicado: (2021)

Thrombelastography and sepsis
por: Puana, Rudolph, et al.
Publicado: (2007)

Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele
por: Qian, Wenwen, et al.
Publicado: (2022)

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
por: Pettersen, Alf-Aage R, et al.
Publicado: (2011)

Clinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300 mg loading dose of clopidogrel, measured by thrombelastography
por: Hou, Xu-Min, et al.
Publicado: (2013)

Effect of thrombelastography on timing of coronary artery bypass grafting
por: Yang, Zhiyuan, et al.
Publicado: (2018)

Assessing the Methodology for Calculating Platelet Contribution to Clot Strength (Platelet Component) in Thromboelastometry and Thrombelastography
por: Solomon, Cristina, et al.
Publicado: (2015)

Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant
por: Mehta, Meha P., et al.
Publicado: (2023)

The Role of Thrombelastography in Multiple Trauma
por: Jeger, Victor, et al.
Publicado: (2011)

Thrombelastography Guides Transfusion Strategy
por: Bay Nielsen, Henning
Publicado: (2009)

Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity
por: Chae, Hyojin, et al.
Publicado: (2013)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
por: Danielak, Dorota, et al.
Publicado: (2016)

Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients
por: Marchini, J.F.M., et al.
Publicado: (2017)

The CYP2C19 genotypes and its effect on clopidogrel as an anti-platelet drug among the Arab population
por: Alkattan, Abdullah, et al.
Publicado: (2021)

Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography
por: Wu, Hong-yi, et al.
Publicado: (2019)

Thrombelastography and tromboelastometry in assessing coagulopathy in trauma
por: Johansson, Pär I, et al.
Publicado: (2009)

A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients
por: Hassani Idrissi, Hind, et al.
Publicado: (2018)

Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China
por: Su, Qiang, et al.
Publicado: (2019)

Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes
por: Dong, Peng, et al.
Publicado: (2016)

Impact of CYP2C19 Variants on Clinical Efficacy of Clopidogrel and 1-Year Clinical Outcomes in Coronary Heart Patients Undergoing Percutaneous Coronary Intervention
por: Sun, Hong, et al.
Publicado: (2016)

Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI)
por: Chen, Shuxia, et al.
Publicado: (2017)

CYP2C19 loss‐of‐function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel
por: Ramste, Markus, et al.
Publicado: (2023)

Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review
por: Tekeste, Rahel, et al.
Publicado: (2022)

Antithrombin and hypercoagulability in sepsis: insights from thrombelastography?
por: Hoffmann, Johannes N, et al.
Publicado: (2007)

Procoagulant activity and thrombelastography in Korean hemorrhagic fever.
por: Lee, M., et al.
Publicado: (1986)

The impact of CYP2C19 *2 and *3 polymorphism on clopidogrel response following coronary stenting in Saudi patients with acute coronary syndrome
por: H, Khalaf, et al.
Publicado: (2014)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents
por: Choi, Ik Jun, et al.
Publicado: (2016)

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
por: Varenhorst, Christoph, et al.
Publicado: (2009)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention
por: Bergmeijer, Thomas O., et al.
Publicado: (2020)

Functional Characterization of Human CYP2C9 Allelic Variants in COS-7 Cells
por: Du, Huihui, et al.
Publicado: (2016)

CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel
por: Chen, Yu-Wei, et al.
Publicado: (2022)

Cyp2C19*2 Polymorphism Related to Clopidogrel Resistance in Patients With Coronary Heart Disease, Especially in the Asian Population: A Systematic Review and Meta-Analysis
por: Sun, Ying, et al.
Publicado: (2020)

Prediction of Ischemic Events after Percutaneous Coronary Intervention: Thrombelastography Profiles and Factor XIIIa Activity
por: Kreutz, Rolf P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9bkpp779l7qv893qj270vtbh8b